Virtual Library
Start Your Search
A. Mishra
Author of
-
+
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
-
+
33P - Expression of biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of non-small cell lung carcinoma patients detected by real-time PCR (ID 467)
12:30 - 13:00 | Presenting Author(s): A. Mishra
- Abstract
Background:
Lung cancer is the leading cause of cancer-related death worldwide. In India, lung cancer constitutes 6.9 per cent of all new cancer cases and 9.3 per cent of all cancer related deaths in both sexes. The propensity for tumor biomarkers to be detected in serum at an early disease stage has become an area of interest for clinicians. This study aimed to evaluate the expression of four known serum biomarkers, namely, Isocitrate Dehydrogenase-1(IDH-1), carcinoembryonic antigen(CEA), Tissue Polypeptide Antigen (TPA), cytokeratin19(CYFRA-21-1) in tumor tissue and peripheral blood of patients with non-small cell lung cancer, detected by relative quantification real-time PCR and to analyze the association with benign lung tissue samples.
Methods:
Fifty patients affected by non small cell lung carcinoma of Stage IIIB, in which histopathologically identified 21 patients were adenocarcinoma and 29 patients were squamous lung carcinoma and fifty individuals which affected by benign lung disease were studied in this study. cDNA were made from each sample after taking peripheral blood samples and tissue sample during surgery, extracting total RNA. simultaneously detecting four genes in each sample was examined by the real-time PCR technique.
Results:
The IDH1 was up-regulated in tumor patients compared with corresponding benign lung individuals in tissue samples 36 out of 50 and in blood sample was up-regulated in 40/50, its sensitivity was determined at 72% in tumor tissue sample and 80% in blood sample, CEA was up-regulated 34 out of 50 patients in tissue and in blood sample up-regulated in 41/50, its sensitivity was determined at 68% in tumor tissue sample and 82% in blood sample, TPA was up-regulated 43 out of 50 patients in tissue and in blood sample up-regulated in 45/50, its sensitivity was determined at 86% in tumor tissue sample and 90% in blood sample, CYFRA21-1 was up-regulated 37 out of 50 patients in tissue and in blood sample was up-regulated in 43/50, its sensitivity was determined at 74% in tumor tissue sample and 86% in blood sample.
Conclusions:
Hence, we further validate the known biomarkers both in tissue and peripheral blood and propose their diagnostic and prognostic utility.
Clinical trial identification:
Legal entity responsible for the study:
Institutional Ethical Committee
Funding:
King George's Medical University, Lucknow, India
Disclosure:
All authors have declared no conflicts of interest.
